A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

NCT03819881 ↗

Phase 1 Unknown 60 enrolled Siolta Therapeutics, Inc. Integrium · collab

RandomizedSequentialQuadruple-blindTreatment

Summary

The primary objective of this study is to assess the safety and tolerability of STMC-103H compared to placebo in allergic subjects who are otherwise healthy.

Timeline

Start: 2018-10-10
Primary completion: 2019-11
Completion: 2019-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	STMC-103H	Other / unclassified	—	Oral

A Phase 1b Study of STMC-103H in Multi-Sensitized Allergic Subjects Who Are Otherwise Healthy

Summary

Timeline

Drugs

Indications